Details

Autor(en) / Beteiligte

• Tallantyre, Emma C
• Scurr, Martin J
• Vickaryous, Nicola
• Richards, Aidan
• Anderson, Valerie
• Baker, David
• Chance, Randy
• Evangelou, Nikos
• George, Katila
• Giovannoni, Gavin
• Harding, Katharine E
• Hibbert, Aimee
• Ingram, Gillian
• Jolles, Stephen
• Jones, Meleri
• Kang, Angray S
• Loveless, Samantha
• Moat, Stuart J
• Robertson, Neil P
• Rios, Francesca
• Schmierer, Klaus
• Willis, Mark
• Godkin, Andrew
• Dobson, Ruth

Titel

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

Ist Teil von

• Multiple sclerosis and related disorders, 2022-08, Vol.64, p.103937-103937, Article 103937

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •PwMS on certain DMTs have attenuated response to initial COVID-19 vaccination.•Booster vaccinations result in seroconversion in one third.•Almost half of pwMS on fingolimod seroconverted after a booster vaccine.•COVID-19 T-cell responses are often present in people on ocrelizumab. People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine in this group. PwMS without a detectable IgG response following COVID-19 vaccines 1&2 were invited to participate. Participants provided a dried blood spot +/- venous blood sample 2–12 weeks following COVID-19 vaccine 3. Humoral and T cell responses to SARS-CoV-2 spike protein and nucleocapsid antigen were measured. Of 81 participants, 79 provided a dried blood spot sample, of whom 38 also provided a whole blood sample; 2 provided only whole blood. Anti-SARS-CoV-2-spike IgG seroconversion post-COVID-19 vaccine 3 occurred in 26/79 (33%) participants; 26/40 (65%) had positive T-cell responses. Overall, 31/40 (78%) demonstrated either humoral or cellular immune response post-COVID-19 vaccine 3. There was no association between laboratory evidence of prior COVID-19 and seroconversion following vaccine 3. Approximately one third of pwMS who were seronegative after initial COVID-19 vaccination seroconverted after booster (third) vaccination, supporting the use of boosters in this group. Almost 8 out of 10 had a measurable immune response following 3rd COVID-19 vaccine.